iOmx Therapeutics

iOmx Therapeutics is a biopharmaceutical company focused on developing first-in-class cancer immunotherapies addressing novel immune checkpoints hijacked by cancer cells. Utilizing its iOTarg™ high-throughput screening platform, iOmx has identified a number of proprietary tumor-associated next-generation immune checkpoints and is advancing a preclinical stage pipeline of promising drug candidates that have the potential to address cancers that are resistant to current immunotherapies. The company’s lead program IMT-07 targets SIK3, an immune protective kinase in multiple solid tumors; the IMT-18 program is a first-in-class antibody designed to inhibit IGSF11, an immune checkpoint in PD1/PD-L1-resistant tumors. Founded in 2016 based on the work of its scientific founders Philipp Beckhove, MD, and Nisit Khandelwal, Ph.D., conducted at the German Cancer Research Center, iOmx is backed by international venture capital investors, such as Wellington Partners, Sofinnova Partners and M Ventures as well as MIG Capital and Athos Service. iOmx is based in Martinsried/Munich, Germany.

Latest News Entry
iOmx Therapeutics raises EUR 65 million in Series B round
  • Financing round with top-tier life science venture capitalists, led by Athos Service and MIG Capital, joined by existing shareholders
  • The new funds will be used to advance iOmx´ lead programs IMT-07 andIMT-18, both addressing novel immune checkpoint targets in oncology
iOmx Therapeutics Announces Discovery of Novel, Druggable Immune-Checkpoint Targets

iOTarg™ Platform Identifies SIK3 Kinase as an Immune Checkpoint in Multiple Solid Tumors and IGSF11 as an Immune Checkpoint in PD-L1 Resistant Tumors
iOmx is Building a Pipeline of Monoclonal Antibodies and Kinase Inhibitors TargetingNovel Checkpoints with Quality of PD-1/PD-L1 Axis

iOmx Therapeutics raises EUR 40 million in Series A round

Martinsried / Munich, Germany, September 22, 2016 -- iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on novel immune checkpoint targets, today announced the closing of a Series A financing round totaling EUR 40 million. MPM Capital and Sofinnova Partners co-led the round, and were joined by Wellington Partners and M Ventures.

all portfolio news